Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Inclusion Criteria:

• cirrhotic patients presented with actively bleeding

Exclusion Criteria:

• other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)